Protionamide

Summary

Protionamide (CHEMBL1378024) is a phase-3 clinical-stage small molecule (ATC J04AD01); indicated across 2 conditions including tuberculosis and pulmonary tuberculosis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: J04AD01
• Indications: 2 conditions
• Clinical trials: 4
• Chemistry: 180.27 Da · C9H12N2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1378024
Name	Protionamide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	666418
ATC	J04AD01
Molecular formula	C9H12N2S
Molecular weight	180.27
InChIKey	VRDIULHPQTYCLN-UHFFFAOYSA-N

SMILES: CCCC1=NC=CC(=C1)C(=S)N

IUPAC name: 2-propylpyridine-4-carbothioamide

Also known as: Ektebin, NSC-758962, Peteha, Prothionamide, Protionamida, Protionamide, Protionamidum, RP 9778, RP-9778, TH-1321, Trevintix, SID26749033

Patent coverage: 842 distinct patent families (2,868 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 2,855 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Lysine-specific demethylase 4E, Prelamin-A/C, Thyrotropin receptor, Tyrosinase, Cytochrome P450 3A4.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	6.1	Potency	794.3	nM	CHEMBL_ACT_3661378
O42713	5.35	IC50	4500	nM	CHEMBL_ACT_16406262

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
tuberculosis	4	MONDO:0018076	MONDO:0018076
pulmonary tuberculosis	3	MONDO:0006052	EFO:1000049

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	2
PHASE4	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05306223	PHASE4	UNKNOWN	A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China
NCT06081361	PHASE3	ACTIVE_NOT_RECRUITING	Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
NCT02409290	PHASE3	COMPLETED	The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
NCT00042289	Not specified	COMPLETED	Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).